Description

Plasmid DNA, as a non-viral vector for gene delivery, has wide applications in preventive vaccines for infectious diseases, tumor therapy, protein replacement therapy, and other fields. However, therapeutic plasmid DNA faces several challenges. There are risks associated with the integration of plasmid DNA into the genome of target cells. CpG motifs present in plasmid DNA sequences may have immune-stimulating effects. Bacteria present in the human body may undergo plasmid transformation, leading to plasmid DNA replication and bacterial development of resistance. Additionally, DNA fragments containing only transcription units obtained by restriction enzyme digestion or PCR amplification are highly susceptible to degradation by nucleases.

LC-dsDNA (Linear, covalent closed, double-strand DNA), also known as linear covalently closed double-stranded DNA, possesses free, non-cohesive 3' and 5' ends, making it a small, linear double-stranded DNA structure. LC-dsDNA lacks scaffold information and serves solely for the expression of target genes. Due to its small molecular weight, it exhibits high efficiency in cell transfection. Moreover, its ability to trigger levels of humoral and cellular immunity comparable to those achieved by plasmid DNA vaccines in antigen expression and in vivo murine models offers effective protection against viral infections. Introducing LC-dsDNA into target cells enables the introduction and expression of specific genes within cells, offering significant advantages in clinical applications and safety.

Features

Compared to traditional DNA plasmids, LC-dsDNA has the following advantages:

1. Elimination of plasmid backbone and irrelevant exogenous sequences reduces risks, resulting in higher safety.
2. Reduction of CpG motifs lowers the risk of triggering immune responses.
3. Not influenced by plasmid backbone copy numbers, leading to higher yields.
4. Better expression in mammalian organisms, requiring less DNA for each transfection.

In contrast to DNA fragments obtained through PCR amplification or enzyme digestion, LC-dsDNA forms a covalently closed structure with self-circularization at the 3' end, making it resistant to nuclease degradation and thus exhibiting higher stability.

Deliverable

We have extensive experience in custom synthesis of research-grade LC-dsDNA and offer one-stop services including gene synthesis, plasmid preparation, and LC-dsDNA synthesis. We can synthesize LC-dsDNA ranging from 200 to 8000 base pairs and optimize customization for various downstream applications. Our delivered products exhibit high yield, high purity, and low residual impurities, making them suitable for early-stage research in numerous fields such as nucleic acid (DNA, mRNA) vaccine and drug development, as well as gene and cell therapy (GCT).

Service

Quality Control

Applications

• Template for mRNA IVT: LC-dsDNA serves as a template for mRNA in vitro transcription (IVT), with bacterial plasmid residue being less than 1/100 of traditional methods. We offer rapid synthesis services for 70-150 polyA templates.
• Gene Editing: LC-dsDNA can serve as a homology-directed repair (HDR) template for gene knock-in in CRISPR/Cas gene editing technology. With linear closed-end structure, it is resistant to cellular nucleases, enhancing editing efficiency, while the closed structure reduces the risk of non-homologous end joining.
• Non-viral Vector for Gene Therapy: As a non-viral vector for gene delivery, LC-dsDNA exhibits higher payload capacity, greater transgene ability, lower toxicity, minimal immunogenicity, and increased safety.

SBS Genetech is recognized as one of the global major leading industry players in Gene Synthesis by third-party market researchers. For more details, please visit GENE SYNTHESIS MARKET SIZE & SHARE ANALYSIS - GROWTH TRENDS & FORECASTS (2023 - 2028).

Only for research and not intended for treatment of humans or animals

Journals Using SBS Genetech Products                                       Universities Using SBS Genetech Products

SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory